

Market Round-up

V21 – 12th October 2018

General Market News:

- **GSK** to hold on to its cephalosporins antibiotics business in the UK, but nearly 200 workers will be let go
[LINK](#)
- **MSD** have announced positive efficacy results from the phase III DRIVE-AHEAD study, evaluating the efficacy and safety of **Delstrigo** in treating HIV-1.
[LINK](#)
- **MSD's** HPV vaccine **Gardasil 9** expanded for people aged 27 to 45
[LINK](#)
- **Pfizer** hit with multi-plaintiff suit over anti-seizure drug **Dilantin**
[LINK](#)
- Novartis launches digital health innovation lab the Novartis Biome
[LINK](#)
- Minister outlines what increased Health budget will be spent on in 2019
[LINK](#)
- **Mundipharma** strengthens position as a leader in biosimilars with acquisition of development company Cinfa Biotech
[LINK](#)

NCPE Drug Updates

- A full pharmacoeconomic assessment has been recommended for **Roche's Ocrelizumab (Ocrevus®)** - indicated for the treatment of adult patients with early primary progressive multiple sclerosis
[LINK](#)
- A full pharmacoeconomic assessment has been recommended for **Merck's Avelumab (Bavencio®)** - indicated for the treatment of adults with metastatic Merkel Cell Carcinoma.
[LINK](#)
- A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of **Bayer's Rivaroxaban** – indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease.
[LINK](#)

Biosimilars:

- Moody's picks 5 early winners in biosimilar market - **Pfizer, Biogen, Novartis, Amgen** and **Mylan**
[LINK](#)

- **Merck** signs US\$117 mln deal with U.S. government on **Bioepis biosimilar**
[LINK](#)
- Ten things pharmacists should know about biologics and biosimilars
[LINK](#)

Drug Approvals:

- FDA approved expanded use for **MSD's Gardasil 9** HPV vaccine
[LINK](#)
- NICE expands backing for **Pfizer's Mylotarg**
[LINK](#)
- **Gilead** has struck a deal with NHS England that allows some adults with lymphoma access to its CAR-T therapy **Yescarta**.
[LINK](#)
- FDA, EMA agree to review **Novartis** therapy **Siponimod** to treat SPMS.
[LINK](#)
- **Pfizer's Mylotarg** has been approved by the NHS as a restricted use treatment for a certain type of acute myeloid leukaemia (AML).
[LINK](#)

Drug Approval Submissions:

- **Novartis** is seeking approval on both sides of the Atlantic for use of experimental multiple sclerosis therapy **siponimod** to treat secondary progressive forms of the disease.
[LINK](#)
- **Novartis** presents positive data on Sickle Cell Disease drug **crizanlizumab** & expects a filing in the US during 2019.
[LINK](#)

Further Reading:

GSK Consumer Healthcare: A digital transformation case study
[LINK](#)

Fluoroquinolone and quinolone antibiotics: PRAC recommends new restrictions on use following review of disabling and potentially long-lasting side effects
[LINK](#)
